Simple Summary Immune checkpoint inhibitors (ICI) have dramatically changed the
landscape of metastatic urothelial carcinoma (UC). However, optimal duration of treatment …

Urothelial carcinoma is the sixth most common malignancy in the US. While most patients
present with non-muscle-invasive disease, many will develop recurrent disease including …

Immunotherapy has revolutionized the systemic treatment of solid tumors, including
advanced urothelial carcinoma (aUC), providing durable responses with a favorable safety …

Until 5 years ago, systemic therapeutic options for urothelial carcinoma, the most common
form of bladder cancer, had been limited to cisplatin-based regimens (methotrexate …

Abstract Purpose of Review Advanced urothelial carcinoma (aUC) has long been treated
preferably with cisplatin-based chemotherapy, but many patients are cisplatin-ineligible …

Introduction: The efficacy of immune checkpoint inhibitors has been shown in many
malignancies. Urothelial cancers have a high mutational load and also express a high level …

Bladder cancer is the sixth most common cancer in the US and most tumors have urothelial
(transitional cell) histology. Platinum-based chemotherapy has long been the standard of …

Purpose Although immunotherapy has a long history in the treatment of urothelial
carcinoma, its use was limited to intravesical therapy for nonmuscle invasive disease. The …

Traditional cisplatin-based chemotherapy has long been the mainstay treatment for
advanced urothelial carcinoma (UC), but the emergence of immune checkpoint inhibitors …

Simple Summary Metastatic urothelial carcinoma is sensitive to immunomodulation. Immune
checkpoint inhibitors (ICIs) have been FDA approved for use as single agents to treat locally …